Platinum

• Constipation while traveling*ICD-10: K59.00

Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.

1. 1Fatigue676.5%
2. 2Disease Progression656.3%
3. 3Diarrhoea595.7%
4. 4Off Label Use565.4%
5. 5Nausea515.0%
6. 6Death464.5%
7. 7Pain464.5%
8. 8Malignant Neoplasm Progression434.2%
9. 9Asthenia383.7%
10. 10Neutropenia363.5%
11. 11Vomiting363.5%
12. 12Anaemia353.4%
13. 13Drug Ineffective353.4%
14. 14Thrombocytopenia343.3%
15. 15Headache333.2%

Recent PubMed references pinned to Platinum as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Primary Platinum-Resistant Ovarian Cancer: Clinicopathologic Correlates and Outcomes From a Multicenter Prospective Indian Registry.
  JCO global oncology · 2026 · Sehrawat A, Singh L, Sundriyal D, et al.
  PMID 42202250DOI 10.1200/GO-25-00650
• Optimal Duration of Adjuvant Platinum-Etoposide in High-Risk Merkel Cell Carcinoma.
  Medicina (Kaunas, Lithuania) · 2026 · Brenner R, Edri HTF, Rouvinov K, et al.
  PMID 42195135DOI 10.3390/medicina62050882
• UV-Driven Degradation of Amantadine over a Photodeposited Pt/TiO(2) Porous Ceramic Composite and Transformation Pathways.
  Journal of agricultural and food chemistry · 2026 · Xu Y, Zhang D, Ma Z, et al.
  PMID 42186820DOI 10.1021/acs.jafc.6c01913
• AIE-Pt metallacages with water-sensitized type I photodynamics for enhanced cancer therapy.
  Biomaterials · 2026 · Li W, Zhu ZH, Hu Y, et al.
  PMID 42184752DOI 10.1016/j.biomaterials.2026.124336
• Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.
  Frontiers in public health · 2026 · Jin L, Han L, Zeng J, et al.
  PMID 42180459DOI 10.3389/fpubh.2026.1802471
• Understanding the synergistic role of Ni/Pt doping and γ-Al(2)O(3) support in tuning CO(2) adsorption and activation on Cu(13) nanoclusters.
  Journal of molecular graphics & modelling · 2026 · Abuhassan Q, Farah H, Waleed OS, et al.
  PMID 42160874DOI 10.1016/j.jmgm.2026.109448
• Exonuclease I-assisted recycling strategy coupled with Cu-Pt bimetallic nanozyme catalysis for ultrasensitive electrochemical aptasensing of deoxynivalenol.
  Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · Wei H, Yiwei X, Yaojie G, et al.
  PMID 42127752DOI 10.1016/j.bioelechem.2026.109319
• Potential-resolved single-nanoparticle collision electrochemistry for simultaneous quantification of MCF-7 and SK-BR-3 cells.
  Biosensors & bioelectronics · 2026 · Qin F, Yu W, You Z, et al.
  PMID 42127679DOI 10.1016/j.bios.2026.118783

The 10 most recently updated of 5,686 ClinicalTrials.gov registrations naming Platinum as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
  Recruiting · Phase 2 · Phase 3 · Interventional · 189 enrolled · National Cancer Institute (NCI)
  NCT05058651updated 2026-06-12
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
  Active not recruiting · Phase 2 · Interventional · 120 enrolled · M.D. Anderson Cancer Center
  NCT04592237updated 2026-06-12
• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
  Recruiting · Phase 2 · Interventional · 406 enrolled · Milton S. Hershey Medical Center
  NCT07321912updated 2026-06-12
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
  Recruiting · Phase 2 · Phase 3 · Interventional · 1,122 enrolled · National Cancer Institute (NCI)
  NCT05691478updated 2026-06-12
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
  Recruiting · Phase 2 · Interventional · 50 enrolled · National Cancer Institute (NCI)
  NCT06064097updated 2026-06-12
• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
  Recruiting · Phase 2 · Interventional · 60 enrolled · National Cancer Institute (NCI)
  NCT06406465updated 2026-06-12
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  Recruiting · Phase 1 · Interventional · 154 enrolled · Coherus Oncology, Inc.
  NCT06657144updated 2026-06-12
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  Recruiting · Phase 3 · Interventional · 1,210 enrolled · National Cancer Institute (NCI)
  NCT04267848updated 2026-06-12
• Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
  Recruiting · Phase 2 · Interventional · 108 enrolled · National Cancer Institute (NCI)
  NCT07281417updated 2026-06-12
• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Recruiting · Phase 3 · Interventional · 1,023 enrolled · Merck Sharp & Dohme LLC
  NCT07216703updated 2026-06-12

Frequently asked questions

What is Platinum used for?

According to FDA labeling, Platinum carries indications including: Constipation while traveling*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.